A retrospective study was conducted involving eight patients diagnosed as corticosteroid-induced facial erythema. Each patient underwent a single session of FRM. Evaluative measures included Clinician\'s Erythema Assessment (CEA), Patient\'s Self-Assessment (PSA), assessment of telangiectasia severity, procedure-associated pain (10-point scale), patient satisfaction (3-point scale) and secondary outcomes.
The study found a 75% success rate and 100% effectiveness rate in alleviating erythema symptoms. CEA and PSA scores decreased by 67.7% and 78.1%, respectively. No cases of erythema rebound were recorded during the 3-month follow-up period.
FRM demonstrated effectiveness and safety in treating facial erythema, offering promising advancement in dermatologic therapeutics.
方法:进行了一项回顾性研究,纳入了8例被诊断为皮质类固醇激素性面部红斑的患者。每位患者接受一次FRM治疗。评估措施包括临床医生红斑评估(CEA),患者自我评估(PSA),毛细血管扩张严重程度的评估,手术相关疼痛(10分量表),患者满意度(3分量表)和次要结果。
结果:研究发现,在缓解红斑症状方面,成功率为75%,有效率为100%。CEA和PSA评分分别下降67.7%和78.1%,分别。在3个月的随访期间,没有记录到红斑反弹的病例。
结论:FRM显示出治疗面部红斑的有效性和安全性,在皮肤病治疗方面提供有希望的进展。